Evolving strategies for addressing CAR T-cell toxicities
The field of chimeric antigen receptor (CAR) T-cell therapy has grown from a fully
experimental concept to now boasting a multitude of treatments including six FDA-approved …
experimental concept to now boasting a multitude of treatments including six FDA-approved …
[HTML][HTML] Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma
N Esteghamat, A Tsumura… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease
with poor prognosis and limited therapeutic options. High-dose chemotherapy with …
with poor prognosis and limited therapeutic options. High-dose chemotherapy with …
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review
G Ghilardi, ZS Hasanali… - … for ImmunoTherapy of …, 2025 - jitc.bmj.com
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-
cell malignancies, and additional indications are being evaluated. In this review, we survey …
cell malignancies, and additional indications are being evaluated. In this review, we survey …
The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies
M Du, RTM Mayombo, J Liu, Y Zhang, D Liao, Y Hu… - 2025 - researchsquare.com
Background: CAR-T therapy has revolutionized treatment for relapsed/refractory B-cell
malignancies, including B-ALL and DLBCL. However, the influence of obesity and related …
malignancies, including B-ALL and DLBCL. However, the influence of obesity and related …
[引用][C] Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma
D Dima, CS Sauter - … and Cellular Therapy, Official Publication of …, 2024 - astctjournal.org
journal homepage: www. astctjournal. org but similar high-grade toxicity rates. Less than
20% of the entire cohort aged> 70 years. 15 In this current study by Johnson et al, 11 65 out …
20% of the entire cohort aged> 70 years. 15 In this current study by Johnson et al, 11 65 out …